Matthew I. Gross, based in Walnut Creek, California, is a notable inventor with a significant contribution to the field of biochemistry and pharmaceuticals. With a portfolio of 7 patents, Gross's innovations primarily focus on advanced therapeutic methods aimed at treating challenging medical conditions.

Latest Patents

Among his latest patents, Gross has developed:

1. **Arginase Inhibitor Combination Therapies** - This patent discusses methods for treating or preventing diseases by administering an arginase inhibitor along with a composition comprising immune cells.

2. **Combination Therapy with Glutaminase Inhibitors and Immuno-Oncology Agents** - This invention outlines methods for treating cancer and various diseases using a combination of glutaminase inhibitors and immuno-oncology therapeutic agents, including inhibitors of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.

Career Highlights

Matthew I. Gross currently works at Calithera Biosciences, Inc., a company dedicated to developing cancer therapeutics. His extensive knowledge and innovative approaches contribute significantly to the company's mission of combating serious diseases through cutting-edge treatments.

Collaborations

In his professional journey, Gross has collaborated with esteemed coworkers such as Susan D. Bromley and Francesco Parlati. These collaborations have undoubtedly enhanced the research and development efforts within his field, fostering innovative breakthroughs.

Conclusion

Matthew I. Gross exemplifies the spirit of innovation in the field of biochemistry and pharmaceuticals. His commitment to developing effective therapies for complex diseases showcases the important role inventors play in advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.